ИНТРАВИТРЕАЛНАТА ТЕРАПИЈА КАЈ ДИЈАБЕТИЧЕН МАКУЛАРЕН ЕДЕМ: АКТУЕЛЕН ТРЕТМАН
Journal
MEDICUS
Date Issued
2017
Author(s)
Abstract
Aim: To show the effectiveness of current treatment for diabetic macular edema (DME), the primary monotherapy
for intravitreal administration of Avastin (Bevacizumab), and combined treatment with laser photocoagulation.
Background: Laser photocoagulation remains the standard treatment, but numerous studies confirm the
applicability and benefits of additional therapy for DME as the application of anti VEGF and intravitreal
administration of corticosteroids, which promise improvement of visual acuity.
Material and Methods: Retrospective, observational, noncomparative series of cases, involving 51 eyes, with DME
treated with 0, 04 ml / 1, 25 mg Bevacizumab according “pro re nata regimen”, and separated into groups indicted
by the primary treatment. Patients were reviewed for 12 months, underwent complete eye examination.
Results: The first group with intravitreal administration of Bevacizumab, showed significant improvement of VA
for 0, 22 ± 0, 1. In the second group, with combined therapy, improved VA to 0, 17± 0, 8 and the third group with
laser, the VA for 0,16 ± 0, 04
After the measurements of the control OCT analysis, in the first group there is a decrease in CMT for 82, 69
µm, received injections 3.42 on average. In second group with an average of 1 laser and intravitreal applications
received 3, 52, decrease is 123, 73 µm and in the third group CMT decreased by 1, 71 µm.
Conclusion: Intravitreal administration of Bevacizumab is effective in improving VA in patients with DME, but
the benefits are limited to a certain range. Combined treatment resulted in a significant reduction in the need for
intravitreal administration to control edema.
for intravitreal administration of Avastin (Bevacizumab), and combined treatment with laser photocoagulation.
Background: Laser photocoagulation remains the standard treatment, but numerous studies confirm the
applicability and benefits of additional therapy for DME as the application of anti VEGF and intravitreal
administration of corticosteroids, which promise improvement of visual acuity.
Material and Methods: Retrospective, observational, noncomparative series of cases, involving 51 eyes, with DME
treated with 0, 04 ml / 1, 25 mg Bevacizumab according “pro re nata regimen”, and separated into groups indicted
by the primary treatment. Patients were reviewed for 12 months, underwent complete eye examination.
Results: The first group with intravitreal administration of Bevacizumab, showed significant improvement of VA
for 0, 22 ± 0, 1. In the second group, with combined therapy, improved VA to 0, 17± 0, 8 and the third group with
laser, the VA for 0,16 ± 0, 04
After the measurements of the control OCT analysis, in the first group there is a decrease in CMT for 82, 69
µm, received injections 3.42 on average. In second group with an average of 1 laser and intravitreal applications
received 3, 52, decrease is 123, 73 µm and in the third group CMT decreased by 1, 71 µm.
Conclusion: Intravitreal administration of Bevacizumab is effective in improving VA in patients with DME, but
the benefits are limited to a certain range. Combined treatment resulted in a significant reduction in the need for
intravitreal administration to control edema.
File(s)![Thumbnail Image]()
Loading...
Name
medicus-shkurt-2017.pdf
Size
8.73 MB
Format
Adobe PDF
Checksum
(MD5):5678ed5cee62cdabc0e72bc002f2a768